Table II.
Therapeutic effect | Sorafenib (n=20) | NFP (n=44) |
---|---|---|
CR | 0 (0) | 10 (23) |
PR | 2 (10) | 21 (48) |
SD | 8 (40) | 8 (18) |
PD | 10 (50) | 5 (11) |
NFP, new 5-fluorouracil and cisplatin therapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease Results are presented as n (%).